Малайзія - англійська - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novo nordisk pharma (malaysia) sdn. bhd. - liraglutide -

Ізраїль - англійська - Ministry of Health

novo nordisk ltd., israel - liraglutide - solution for injection - liraglutide 6 mg / 1 ml - liraglutide - adultssaxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (bmi) of •≥30 kg/m² (obesity), or •≥27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension or dyslipidaemia, and who have failed a previous weight management intervention. treatment with saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight.adolescents (≥12 years)saxenda can be used as an adjunct to a healthy nutrition and increased physical activity for weight management in adolescent patients from the age of 12 years and above with:• obesity (bmi corresponding to ≥30 kg/m2 for adults by international cut-off points)* and• body weight above 60 kg. treatment with saxenda should be discontinued and re-evaluated if patients have not lost at least 4% of their bmi or bmi z score after 12 weeks on the 3.0 mg/day or maximum tolerated dose. re-evaluation should be performed periodically

ПАР - англійська - South African Health Products Regulatory Authority (SAHPRA)

novo nordisk (pty) ltd û (rivonia) - injection - see ingredients - each 1,0 ml solution contains liraglutide 6,0 mg

ПАР - англійська - South African Health Products Regulatory Authority (SAHPRA)

sanofi-aventis south africa (pty) ltd - injection - see ingredients - each 1,0 ml solution contains insulin glargine 100,00 units lixisenatide 33,0 ug

ПАР - англійська - South African Health Products Regulatory Authority (SAHPRA)

sanofi-aventis south africa (pty) ltd - injection - see ingredients - each 1,0 ml solution contains insulin glargine 100,00 units lixisenatide 50,0 ug

ПАР - англійська - South African Health Products Regulatory Authority (SAHPRA)

sanofi-aventis south africa (pty) ltd - injection - see ingredients - each 1,0 ml solution contains insulin glargine 100,00 units lixisenatide 33,0 ug

ПАР - англійська - South African Health Products Regulatory Authority (SAHPRA)

sanofi-aventis south africa (pty) ltd - injection - see ingredients - each 1,0 ml solution contains insulin glargine 100,00 units lixisenatide 50,0 ug

Танзанія - англійська - Tanzania Medicinces & Medical Devices Authority

lincoln pharmaceuticals limited, india - paracetamol - solution for injection - 150

Європейський Союз - англійська - EMA (European Medicines Agency)

novo nordisk a/s - semaglutide - obesity; overweight - antiobesity preparations, excl. diet products - wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial body mass index (bmi) of- ≥30 kg/m² (obesity), or- ≥27 kg/m² to

Ізраїль - англійська - Ministry of Health

novo nordisk ltd., israel - semaglutide - solution for injection - semaglutide 0.68 mg / 1 ml - semaglutide - wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial body mass index (bmi) of • ≥30 kg/m2 (obesity), or • ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.